Table 3.
Univariable and multifactorial analysis for overall survival (N = 36).
| Variable | Univariable Analysis | Multivariable Analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Age (years) | 0.351 | |||
| ≤50 | Reference | |||
| >50 | 0.490 (0.137–1.755) | |||
| ECOG | 0.235 | |||
| 1 | Reference | |||
| 0 | 0.457 (0.086–2.433) | |||
| Gender | 0.619 | |||
| Male | Reference | |||
| Female | 0.733 (0.201–2.678) | |||
| Lesion site | ||||
| Upper 1/3 | Reference | |||
| Middle 1/3 | 0.726 (0.035–2.155) | 0.245 | ||
| Lower 1/3 | 0.632 (0.042–1.232) | 0.361 | ||
| Pre-BMI(Kg/m2) | 0.764 | |||
| Underweight (<18.5) | Reference | |||
| Normal (≥18.5) | 0.731 (0.119–4.499) | |||
| Post-BMI(Kg/m2) | 0.978 | |||
| Underweight (<18.5) | Reference | |||
| Normal (≥18.5) | 0.979 (0.209–4.578) | |||
| Borrmann type | 0.792 | |||
| III–IV | Reference | |||
| I–II | 0.814 (0.193–3.435) | |||
| Histological | 0.737 | |||
| Low | Reference | |||
| High-moderate | 0.770 (0.144–4.103) | |||
| cT staging | 0.445 | |||
| T4 | Reference | |||
| T3 | 0.458 (0.098–2.136) | |||
| cN staging | 0.539 | |||
| N3 | Reference | |||
| N1–N2 | 0.622 (0.163–2.378) | |||
| Lesion size(cm) | 0.574 | |||
| ≥5 | Reference | |||
| <5 | 0.647 (0.167–2.505) | |||
| FCC | 0.001 | 0.011 | ||
| Negative | Reference | Reference | ||
| Positive | 5.617 (1.190–26.510) | 5.164 (2.146–14.709) | ||
| Sarcopenia | ||||
| Non-Sarcopenic | Reference | Reference | ||
| Pre-treatment Sarcopenia | 8.043 (1.280–50.520) | 0.001 | 6.341 (1.269-18.943) | 0.001 |
| Newly developed Sarcopenia | 4.740 (0.575-39.090) | 0.035 | 3.189 (1.023-9.811) | 0.012 |
| ΔSMI (%)/50 days | 0.000 | 0.002 | ||
| No-SML | Reference | Reference | ||
| SML | 17.031 (3.028–95.840) | 10.234 (2.532–54.231) | ||
ECOG, Eastern Cooperative Oncology Group; SML, Significant muscle loss; FCC, Free cancer cells.